Project Grant R21HL177578
Award Date
1/15/25
Completion Date
1/14/27
Dollars Obligated
$127K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) is providing $2,275,731 to the Icahn School of Medicine at Mount Sinai to conduct research on deriving hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs). The goal is to understand the transcriptional and signal requirements for generating this unique population of CD34+ progenitor cells that can home to bone marrow and...
The Department of Health and Human Services' National Heart, Lung, and Blood Institute (NHLBI) awarded a $515,160 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, active from April 15, 2024 to March 31, 2029, will support research to understand the role of DNA methyltransferase 3A (DNMT3A) in regulating graft-versus-host disease (GVHD) and the graft-versus-tumor (GVT) effect in allogeneic hematopoietic cell...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is providing $1,014,000.00 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The research, which is scheduled to take place from September 1, 2024 to August 31, 2028, will leverage the institution's expertise in areas such as cancer biology, immunology, and clinical...
The National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,462 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Icahn School of Medicine at Mount Sinai. The grant, effective September 15, 2024 through June 30, 2028, supports research to define the role of the epigenetic regulator SIN3A in regulating the BMPR2 gene and pulmonary artery endothelial cell (PAEC) dysfunction in pulmonary arterial hypertension (PAH). The project aims to...
This federal Project Grant award in the amount of $2,594,544 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate how mucin-degrading intestinal bacteria like Akkermansia and Bacteroides contribute to intestinal graft-versus-host disease (GVHD) and neutropenic fever in patients undergoing allogeneic hematopoietic cell transplantation (allo HCT). The 5-year grant,...
This federal Project Grant award of $202,800.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate "Spatial Copy Number and Morphologic Alterations in Early Lung Carcinogenesis." The award period runs from September 30, 2025 to September 29, 2026. ISMMS, a renowned academic medical center and research institution in New York City, will...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $827,356 to the Icahn School of Medicine at Mount Sinai for a study on advanced multi-parametric imaging techniques to assess response to immune suppressant therapy in patients with active cardiac sarcoidosis.
The key products and services to be delivered under this 5-year grant include:
Prospective evaluation of cardiac MRI, PET, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $252,854 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Icahn School of Medicine at Mount Sinai to develop computational methods for linking single-cell RNA sequencing (scRNAseq) data to physiological predictions of cardiac function.
The key objectives are to: 1) Use scRNAseq to characterize the subtypes and abundances of cardiomyocytes derived from induced pluripotent stem cells; 2) Perform simulations...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a mixed-method study to investigate the impact of school-based policies on adolescent cardiovascular health and maternal health outcomes. The $777,954 award, effective February 1, 2025 through November 30, 2029, will enable the Icahn School of Medicine at Mount Sinai to:
Assess the association between school environment attributes,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,181,696 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) to validate an artificial intelligence (AI) technology for accurately measuring skin erythema, a key biomarker of chronic graft-versus-host disease (cGVHD), from patient photographs. The 5-year project will leverage a unique database of over 11,000 photographs and clinical information from diverse cGVHD patients...